Mechanistically, mounting evidence suggests that SLC7A11 is overexpressed in many cancers; in particular, multiple factors reverse tumor suppression by stabilizing or upregulating SLC7A11 in sorafenib- and cisplatin-resistant cells [24,89,92,93 ]. This evidence concerns the gene SLC7A11 and neoplasm.